Pilot Study of Longitudinal Plasma PD-L1 Testing with Immunotherapy in Lung Cancer

Description

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.

Conditions

Lung Cancer (NSCLC)

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.

Pilot Study of Longitudinal Plasma PD-L1 Testing with Immunotherapy in Lung Cancer

Pilot Study of Longitudinal Plasma PD-L1 Testing with Immunotherapy in Lung Cancer

Condition
Lung Cancer (NSCLC)
Intervention / Treatment

-

Contacts and Locations

Kingsport

Ballad Health Cancer Care, Kingsport, Tennessee, United States, 37660

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. All patients with a diagnosis of stage IV or inoperable stage IIIB NSCLC without planned primary radiation therapy undergoing anti-PD-1/L1 based ICI treatment.
  • 2. Chemo-immune or dual anti-PD-1/L1 with anti-CTLA-4 based regimens are eligible as long as receiving an anti-PD-1/L1 monoclonal antibody.
  • 3. A documented informed consent will be obtained prior to inclusion in the study. All discussions with patients will be held in strictest confidence and out of earshot of the general public. Patients will be fully informed that their participation in the study is voluntary. Patients may decline to be part of the study. Their decision to participate in the study will not affect the care they receive.
  • 1. No anti-PD-1/L1 monoclonal antibody treatment.
  • 2. Planned primary radiation therapy.
  • 3. Small-cell lung cancer histology.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ballad Health,

Study Record Dates

2027-03-01